SYNTHOS RESEARCH

Elevance Health ELV

Healthcare · Medical - Healthcare Plans · Synthos Deep Dive · 2026-08-04

$394.43
Watch
—
—

The Overview

Elevance Health sells health insurance to about 118 million Americans, mostly under the Blue Cross Blue Shield brand. It also owns Carelon, which provides pharmacy, mental-health and care services — partly to its own members and partly to other insurers.

An insurer makes money on the gap between the premiums it collects and the medical bills it pays. That gap has been closing. The share of premiums paid out in medical costs — the company calls it the benefit expense ratio — was 88.9% a year ago and 89.7% in the most recent quarter. Each percentage point is worth roughly $1.65 billion a year of pre-tax profit.

The result is that profits are falling. Adjusted earnings per share were $33.21 in 2024, roughly $30 in 2025, and the company's own guidance for 2026 is at least $26.75 — two consecutive years of decline.

And management has told the market it gets worse before it gets better. Its guidance for the full year is a benefit ratio of 90.2%. The first half ran at 88.3%. That means the second half has to be around 92%. Analysts expect $4.70 per share in the next quarter, against $7.45 in the last one — a 37% drop that everyone is already expecting.

So why is this a "Watch" and not an "Avoid"?

Because of how insurance works, and the clearest statement of it in our research files comes from an outside analyst rather than from the company: "Health insurance is short-tail — one-year liabilities repriced every 12 months — so profit misses aren't perpetual; margins rebuild." An insurer that under-charged this year can raise prices next year. Analysts expect exactly that: earnings recovering to $29.64 in 2027 and $34.00 in 2028.

Meanwhile the balance sheet is improving — debt as a share of capital fell from 42.1% to 40.8% — cash generation doubled in the first half, and the company bought back $1.36 billion of its own shares.

The shares cost $377.905, about 12.8 times what analysts expect for 2027. Our estimate of fair value is $400. Bad case $291; good case $532. That is about $1.77 of possible gain per dollar of loss — real, but below our two-to-one bar.

One thing worth knowing about the accounting. The company's guidance says GAAP earnings will be at least $19.85 per share but adjusted earnings at least $26.75. The difference — $6.90 per share, more than a quarter of the adjusted number — is described only as "net unfavorable items." That is a very large gap to take on trust, and it is one of the reasons we want to see a quarter before acting.

Putting a number on it: our fair-value estimate is $400 against a current price of $394.43 — real upside if our numbers are right.

Our summary metrics

Downside Risk (lower = safer)7/10High

"Rated 7 — a low-beta balance sheet attached to an income statement in visible deterioration, with policy exposure on two fronts. The mechanism is the medical loss ratio and the company publishes it: the benefit expense ratio was 89.7% in the June quarter against 88.9%, and 88.3% in the first half against 87.7% — and full-year guidance reaffirmed on 10 June 2026 is 90.2% plus or minus 50 basis points, which requires roughly 92% in the second half. On $82.3 billion of first-half premium revenue, 100 basis points of benefit ratio is approximately $1.65 billion of annual pre-tax income against FY2025 pre-tax of $6.71 billion. The operating expense ratio also rose 100 basis points to 11.1%. Full-year GAAP guidance of at least $19.85 per share includes 'approximately $6.90 per diluted share of net unfavorable items' — a 25.8% gap to the $26.75 adjusted figure, which is a very large adjustment to accept on trust. The policy exposure runs both ways and is the same variable that has cut HCA's guidance in this same batch: Elevance is the insurer losing exchange members and repricing Medicaid, and the enhanced premium tax credits are a live legislative question. Against all of that: beta is 0.683, debt-to-capital IMPROVED from 42.1% to 40.8% between December and June, senior debt is rated A− by S&P and Baa2 by Moody's, first-half operating cash flow DOUBLED to $6,245 million, and total equity is $45,022 million against $126,438 million of assets."

Growth Quality4/10Moderate

"Rated 4 — revenue grows and earnings do not. Total revenue: $121,867M (FY2020), $138,639M (FY2021), $156,595M (FY2022), $171,340M (FY2023), $176,810M (FY2024), $199,125M (FY2025) — a 10.3% five-year compound rate. The first half of 2026 delivered $100,655M, up 2.0%, with total operating revenue of $99,320M up 1.2%. Earnings run the other way. Diluted GAAP EPS: $17.98, $24.73, $24.28, $25.22, $25.68, $25.12 — flat for four years — and the first half of 2026 delivered $14.73 against $17.33, DOWN 15.0%, with the June quarter at $6.71 against $7.72, down 13.1%. On the adjusted basis consensus uses, the sequence is $33.21 (FY2024), approximately $30 (FY2025) and a company guide of AT LEAST $26.75 for FY2026 — two consecutive years of decline totalling roughly 19%. Consensus then wants $29.636 in FY2027 (14 analysts) and $33.999 in FY2028 (4), which is a recovery to the FY2024 level three years later. What earns the 4 rather than a 3: revenue is genuinely growing, the share count fell 3.5% year on year, first-half operating cash flow doubled to $6,245 million, and the knowledge base's structural claim that health-insurance liabilities reprice every twelve months is a real reason to expect the margin to rebuild. What keeps it at 4: it has not rebuilt yet, and management's own second-half benefit-ratio guidance says it will get worse first."

Exponential Potential3/10Low

"Rated 3 — one strategic asset that the only expert claim in the store says is behind. Elevance serves approximately 118 million people and reports two segments: Health Benefits, at $167,094 million of FY2025 revenue, and Carelon Services at $71,716 million before $41,689 million of eliminations. Carelon is the vertical-integration vehicle — pharmacy, behavioural health, care delivery and services sold both internally and to third parties — and it is the closest thing here to a compounding asset, because services revenue earned from one's own members converts an underwriting margin into a services margin and reduces the volatility that is currently destroying the earnings. The knowledge base's single name-level claim addresses exactly this and is not flattering: 'UNH out-earns peers on integration depth; CVS is retail-heavy, Elevance late, Humana over-concentrated in Medicare Advantage — none match Optum's synergy' (business_breakdowns, 2025-07-12, conviction 80). 'Elevance late' is the whole assessment. Set against that, Carelon's reported revenue grew 33.0% in FY2025 to $71,716 million, which if the segment block can be trusted is a genuine scaling — and the block cannot fully be trusted, since it over-counts by 42.8% in FY2023 and 15.5% in FY2024. A 3: a real strategic direction, a large and growing services business, and an independent assessment that the company is behind the leader in the one thing that matters."

Fair value$400 $291–$532
What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

The Road Ahead

What we expect to matter in each window, and the evidence that would prove us wrong.

Short term 0-6 months

No differentiated view
Driver
"The company has told the market the next two quarters get worse and the market has not fully marked it. Elevance closed 2026-08-04 at $377.905, down 1.27% on 829,000 shares, 11.45% below the 52-week high of $426.79 and 37.45% above the low of $274.93 — and note that the maximum drawdown from peak over the trailing year is 32.79%, three times the current distance from the high, so this is a stock that has already fallen a long way and recovered most of it. It sits 4.6% BELOW a 50-day moving average of $396.11 and 7.5% above a 200-day of $351.45, with RSI at 42.6 and MACD negative at −5.71. Twelve-month return is +37.59% against SPY's +24.26%. The headwind is the company's own guidance: a full-year benefit expense ratio of 90.2% plus or minus 50 basis points against 88.3% actual in the first half implies roughly 92% in the second half, and the third-quarter consensus of $4.70 is 37% below the June quarter's $7.45 adjusted actual. A stock 4.6% below its 50-day average heading into two quarters management has pre-announced as worse is not a favourable short-term setup, whatever the multiple."
What we’re watching
"The 2026-10-21 print against consensus adjusted EPS of $4.70 and revenue of $49,264M. One number decides it: the benefit expense ratio, 89.7% in the June quarter and guided to 90.2% for the full year, which requires roughly 92% in the second half. Above 92% and the full-year guide of at least $26.75 adjusted is at risk; at or below 91% and the guide is conservative. Also watch the operating expense ratio, which rose 100 basis points to 11.1% and is the line management controls; membership by line of business, particularly individual exchange and Medicaid, which are the two policy-exposed books; the composition of the 'approximately $6.90 per diluted share of net unfavorable items' in full-year GAAP guidance, which is a very large adjustment; and the buyback, at $1,358 million in the first half against $1,258 million a year earlier."
Confidence
Medium

Medium term 6-24 months

Neutral
Driver
"The medium term is the repricing cycle, and the knowledge base states the mechanism better than the company does: 'Health insurance is short-tail — one-year liabilities repriced every 12 months — so profit misses aren't perpetual; margins rebuild in rational competitive markets' (business_breakdowns, 2025-07-12, conviction 80). That is the structural case and it is genuine: a health insurer that mis-prices a book in one year reprices it the next, and consensus reflects exactly that expectation, with adjusted EPS recovering from a guided $26.75-plus in FY2026 to $29.636 in FY2027 (14 analysts) and $33.999 in FY2028. The supports are real: total revenue still growing, first-half operating cash flow DOUBLING to $6,245 million from $3,071 million, a debt-to-capital ratio improving from 42.1% to 40.8%, senior debt rated A− by S&P, $1,358 million of first-half buyback taking the share count from 220.7 million to 216.8 million, and a dividend at $1.72 per quarter. Against it: the repricing has to survive competition, and the policy environment for exchanges and Medicaid is the same unresolved legislative question that forced HCA to widen its own exchange assumption from $600-900 million to $1.0-1.2 billion in this batch. Elevance is on the other side of that trade and carries the underwriting risk."
What we’re watching
"Whether the benefit expense ratio peaks in 2026 and falls in 2027 — that single series determines whether the FY2027 consensus of $29.636 is achievable. Whether the enhanced premium tax credits are extended; Elevance is the insurer whose exchange membership and risk pool are directly affected. Whether Medicaid rate negotiations catch up with acuity — the classic lag that has driven this cycle. Whether Carelon's growth is real: reported segment revenue rose 33.0% in FY2025 to $71,716 million, but the segment block over-counts by 42.8% in FY2023 and 15.5% in FY2024, so the level cannot be trusted. Whether the 'approximately $6.90 per diluted share of net unfavorable items' recurs in FY2027 guidance — a 25.8% GAAP-to-adjusted gap that repeats is not an adjustment, it is a cost. Whether the buyback continues near $2.7 billion annualised. And whether the knowledge base's assessment that Elevance is 'late' on vertical integration is answered with disclosed Carelon economics."
Confidence
Low

Long term 2+ years

Neutral
Driver
"Long-run, Elevance is one of a small number of firms with the scale to underwrite American health risk, and scale is most of the moat: approximately 118 million people served, Blue Cross Blue Shield licences across fourteen states, and $199 billion of revenue that gives it negotiating position with every hospital system in its markets — including HCA, which appears elsewhere in this batch on the other side of the same contracts. The structural direction is vertical integration, and Carelon is the vehicle: pharmacy, behavioural health, care delivery and services, at $71,716 million of FY2025 segment revenue before eliminations. If that business converts underwriting volatility into services margin, the multiple this company deserves rises materially. The knowledge base's only name-level assessment says it is behind UnitedHealth in doing so, and 'Elevance late' at conviction 80 from a specialist channel is the most substantive independent judgment in this file. Against a long horizon, the durable question is not competitive but political: roughly 96% of this industry's revenue is set by government programmes or employer negotiation, and the terms are decided outside the company. Neutral: real scale, an unproven integration story, and a permanently political revenue base."
What we’re watching
"Whether Carelon reaches a disclosed, standalone profitability that closes the gap with Optum. Whether medical cost trend structurally normalises — the current cycle is the third material managed-care margin shock in fifteen years. Whether the Blue Cross Blue Shield licensing structure and the associated antitrust settlements remain stable. Whether membership grows: revenue rose 10.3% compounded over five years but the first half of 2026 grew 2.0%, which suggests price rather than volume. Whether the buyback continues to shrink the share count — 254.3 million diluted in FY2020 against 217.9 million in the June quarter, a 14.3% reduction. Whether GAAP and adjusted earnings reconverge; a $6.90-per-share gap sustained across years is a signal in itself. And chief-executive succession: Gail Koziara Boudreaux has led the company since 2017 and was re-elected to the board at the May 2026 annual meeting for a term expiring in 2029."
Confidence
Low

Exponential Potential

Exponential Potential3/10Low

"Rated 3 — one strategic asset that the only expert claim in the store says is behind. Elevance serves approximately 118 million people and reports two segments: Health Benefits, at $167,094 million of FY2025 revenue, and Carelon Services at $71,716 million before $41,689 million of eliminations. Carelon is the vertical-integration vehicle — pharmacy, behavioural health, care delivery and services sold both internally and to third parties — and it is the closest thing here to a compounding asset, because services revenue earned from one's own members converts an underwriting margin into a services margin and reduces the volatility that is currently destroying the earnings. The knowledge base's single name-level claim addresses exactly this and is not flattering: 'UNH out-earns peers on integration depth; CVS is retail-heavy, Elevance late, Humana over-concentrated in Medicare Advantage — none match Optum's synergy' (business_breakdowns, 2025-07-12, conviction 80). 'Elevance late' is the whole assessment. Set against that, Carelon's reported revenue grew 33.0% in FY2025 to $71,716 million, which if the segment block can be trusted is a genuine scaling — and the block cannot fully be trusted, since it over-counts by 42.8% in FY2023 and 15.5% in FY2024. A 3: a real strategic direction, a large and growing services business, and an independent assessment that the company is behind the leader in the one thing that matters."

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ 6%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $394, earnings would have to compound roughly 6% a year for 10 years (9% discount rate). Analysts forecast ~5%/yr, so the market is pricing in about what the Street expects.

Reference table

Street consensus$444.06 (+17.5%) · median $456 · high $498 · low $391 — 3.5% ABOVE spot · 0 strong buy / 27 buy / 11 hold / 0 sell across 38 analysts — not one sell rating
Valuation13.9x FY2026E · 12.8x FY2027E · 11.1x FY2028E · 15.0x trailing GAAP diluted · 1.83x book
Company guidance — filing-verified, reaffirmed 2026-06-10Full-year 2026 shareholders' earnings at least $19.85 per diluted share, "including approximately $6.90 per diluted share of net unfavorable items" · adjusted at least $26.75 · benefit expense ratio 90.2% ± 50 basis points
June quarter — filing-verifiedTotal revenue $50,474M (+1.4%) · total operating revenue $49,826M (+0.8%) · benefit expense ratio 89.7% against 88.9% — up 80 bps · operating expense ratio 11.1% against 10.1% — up 100 bps · pre-tax income $1,937M (−15.5%) · shareholders' net income $1,463M (−16.1%) · diluted EPS $6.71 against $7.72 (−13.1%)
The second-half arithmeticFirst-half benefit expense ratio 88.3%; full-year guidance 90.2%. That implies roughly 92% in the second half — a further 170-basis-point deterioration the company has told the market to expect. Third-quarter consensus of $4.70 is 37% below the June quarter's $7.45 adjusted actual
Balance sheet — improvingDebt-to-capital 40.8% at 2026-06-30 against 42.1% at 2025-12-31 · senior debt rated A− (S&P), BBB+ (Fitch), Baa2 (Moody's) · total equity $45,022M on $126,438M of assets · first-half operating cash flow $6,245M against $3,071M — DOUBLED
Capital return$1,358M repurchased in H1 2026 (against $1,258M a year earlier) plus $749M of dividends at $1.72 per quarter · share count 220,723,898 → 216,841,146 in six months, −1.8% · combined annualised approximately 5.1% of market capitalisation
Conviction1 name-level claim in 52,021 and it says "Elevance LATE" on vertical integration. The most useful claim in the file names no company: "profit misses aren't perpetual; margins rebuild"
Technicals−11.45% from the 52-week high of $426.79; +37.45% above the low of $274.93; maximum twelve-month drawdown −32.79% — three times the current gap to the high; 4.6% BELOW the 50-DMA ($396.11), +7.5% above the 200-DMA ($351.45); RSI 42.6; MACD −5.71; beta 0.683

What the experts actually said

No independent expert claims in the Synthos knowledge base yet for ELV — this dive is fundamentals- and technicals-driven, not panel-driven.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

269311354396438Aug '25Nov '25Jan '26Apr '26Jun '26Aug '2652w hi $42750-DMA 395Price 394200-DMA 35752w lo $281

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Data summary: last close $394.43, 0% below the 50-day average ($395), 10% above the 200-day average ($357) — a mixed trend. 8% below the 52-week high of $427, 40% above the 52-week low of $281.

Bollinger Bands 20-day average ± 2 standard deviations

246297348400451Aug '25Nov '25Jan '26Apr '26Jun '26Aug '2620-day avg 395Price 394

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

Data summary: price $394.43 is currently inside the band (band $383–$408).

RSI (14) momentum gauge · 0–100

705030Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26RSI 49.4

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 49.

MACD 12 / 26 / 9 · trend & momentum

0Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26MACD 2.1signal 1.8

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Data summary: MACD is currently above its signal line by 0.31, positive momentum.

Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago

87100114128141Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26ELV 127XLV (sector) 125S&P 500 119

Solid = ELV · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

066131197262$170BFY23EPS $33$176BFY24EPS $33$199BFY25EPS $30$197BFY26EEPS $27$201BFY27EEPS $30$213BFY28EEPS $34$214BFY29EEPS $41$232BFY30EEPS $48

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$394.43
Market cap$86B
P/E trailing17×
P/E FY26E / FY27E15× / 13×
EV / Sales0.5×
EV / EBITDA13.3×
Gross margin39.0%
Net margin2.5%
Dividend yield1.74%
Beta0.692
52-wk range$281 – $427
RSI(14)47
50 / 200-DMA$395 / $357
12-mo return+27% (SPY +19%)
Street target$444 ($391–$498)
Analyst grades27 Buy · 11 Hold · 0 Sell
FMP ratingB+
Next earnings2026-10-21 (Q3 2026 earnings, 78 days away; vendor consensus adjusted EPS $4.70 and revenue $49,264M — note the $4.70 estimate is 37% BELOW the June quarter's $7.45 adjusted actual, consistent with the company's own guidance that the benefit expense ratio deteriorates further in the second half). Second-quarter results were released 2026-07-15, twenty days before this dive, and beat the consensus adjusted estimate by 20.0% ($7.45 against $6.21) while GAAP diluted EPS FELL 13.1%.

1. The quarter, and the guidance that matters more

From the 10-Q filed 2026-07-15 ($M):

Q2 2026Q2 2025changeH1 2026H1 2025change
Premiums$41,279$41,271+0.0%$82,303$82,158+0.2%
Product revenue$6,264$6,042+3.7%$12,489$11,851+5.4%
Service fees$2,283$2,108+8.3%$4,528$4,177+8.4%
Total operating revenue$49,826$49,421+0.8%$99,320$98,186+1.2%
Net investment income$704$486+44.9%$1,469$1,076+36.5%
Net losses on financial instruments($56)($131)—($134)($595)—
Total revenues$50,474$49,776+1.4%$100,655$98,667+2.0%
Benefit expense$37,024$36,706+0.9%$72,639$72,018+0.9%
Cost of products sold$5,492$5,293+3.8%$10,955$10,276+6.6%
Operating expense$5,547$4,997+11.0%$11,877$10,297+15.3%
Interest expense$364$341+6.7%$721$685+5.3%
Amortisation of other intangibles$110$147−25.2%$222$302−26.5%
Total expenses$48,537$47,484+2.2%$96,414$93,578+3.0%
Income before income tax$1,937$2,292−15.5%$4,241$5,089−16.7%
Income tax expense$483$548—$1,027$1,161—
Shareholders' net income$1,463$1,743−16.1%$3,227$3,926−17.8%
Diluted EPS$6.71$7.72−13.1%$14.73$17.33−15.0%
Average diluted shares217.9M225.8M−3.5%219.1M226.5M−3.3%
Benefit expense ratio89.7%88.9%+80 bps88.3%87.7%+60 bps
Operating expense ratio11.1%10.1%+100 bps12.0%10.5%+150 bps
Effective tax rate24.9%23.9%+100 bps24.2%22.8%+140 bps

Four observations.

First, premiums did not grow at all. $41,279 million against $41,271 million — plus 0.0%. All of the 1.4% total revenue growth came from product revenue, service fees and a 44.9% increase in net investment income. A health insurer whose premium line is flat is either losing members or holding price, and in the current environment probably both.

Second, the benefit ratio and the operating ratio deteriorated together, which is unusual and worse. Benefit expense ratio +80 basis points; operating expense ratio +100 basis points. The first is medical cost trend, which management does not control; the second is administrative, which it does. Operating expense rose 11.0% in the quarter and 15.3% in the half against revenue up 2.0%.

Third, the reported "beat" and the reported decline are both true. The earnings calendar records $7.45 actual against a $6.21 estimate — a 20.0% beat — on the adjusted basis. The GAAP diluted line fell from $7.72 to $6.71. The gap between $7.45 adjusted and $6.71 GAAP is $0.74 in a single quarter, consistent with the full-year guidance of approximately $6.90 of net unfavourable items.

Fourth, the buyback is doing real work. Average diluted shares fell 3.5% year on year, which converted a 16.1% decline in shareholders' net income into a 13.1% decline in EPS.

The guidance, reaffirmed twenty-five days before the print

From the 8-K filed 2026-06-10 (Item 7.01), and this is the most important disclosure in the archive:

> "Company officers will reaffirm the Company's shareholders' earnings guidance for full year 2026 to be at least $19.85 per diluted share, including approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted shareholders' earnings to be at least $26.75 per diluted share... Company officers will also reaffirm full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points."

Three things follow and they are the core of this dive.

The second half is guided materially worse than the first. The first half ran a benefit expense ratio of 88.3%. Full-year guidance is 90.2%. Arithmetically that requires roughly 92% in the second half — a further 170-basis-point deterioration from the June quarter's 89.7%. The company has told the market this in advance, and the third-quarter consensus of $4.70 against the June quarter's $7.45 adjusted shows the street has heard it.

The GAAP-to-adjusted gap is very large. $6.90 per diluted share is 25.8% of the $26.75 adjusted figure and 34.8% of the $19.85 GAAP figure. The guidance describes it only as "net unfavorable items" and adds that it "does not include any other adjustment items beyond those reported in the Company's first quarter 2026 earnings" — so the items are identified somewhere the extraction does not reach. An adjustment of that size, sustained, is not an adjustment; and this dive flags it rather than accepting the adjusted figure uncritically.

And the adjusted trajectory is two years of decline. Consensus epsAvg — which tracks the adjusted basis — reads $33.210 (FY2024), $29.988 (FY2025), $27.135 (FY2026E) and $29.636 (FY2027E). The company's own FY2026 guide of at least $26.75 sits 1.4% below the consensus $27.135.

The rest of the corporate record is routine

The 8-K filed 2026-05-13 records the annual meeting: three directors elected to three-year terms expiring 2029 including Gail K. Boudreaux, Ernst & Young ratified, say-on-pay approved, and a shareholder proposal on corporate political contributions not approved. The 8-K filed 2026-07-15 is the Item 2.02 second-quarter earnings release; Exhibit 99.1 is not in the extraction. There is no spin-off, no segment realignment, no split, no notes offering and no acquisition in the 8-K record — which for a name flagged in advance as a plausible corporate-action candidate is itself a finding.

2. Cash flow, the balance sheet and capital return

First-half 2026 cash flow, from the 10-Q ($M):

H1 2026H1 2025change
Net cash provided by operating activities$6,245$3,071+103.4%
Purchases of property and equipment($522)($463)+12.7%
Repurchase and retirement of common stock($1,358)($1,258)+7.9%
Cash dividends($749)($771)−2.9%
Repayments of long-term borrowings($750)($1,250)—
Net repayments of short-term borrowings($150)($5)—

Operating cash flow doubled while earnings fell 17.8%, driven by a $4,124 million increase in accounts payable and other liabilities and a smaller receivables build ($1,831 million against $4,097 million). For an insurer, operating cash flow leads and lags the income statement through reserve timing, and a doubling alongside falling earnings is a timing effect rather than an improvement in profitability. It is nonetheless real cash and it funded the buyback.

Free cash flow on the conventional construction — $6,245 million less $522 million of capital expenditure — is $5,723 million for the half. That figure should be read with care: for a health insurer, operating cash flow includes movements in medical claims payable, unearned premium and policy liabilities, which are float rather than earnings. This dive does not quote a free-cash-flow yield for that reason, and the vendor's capitalExpenditure field cannot be independently confirmed against a FY2025 line in the extraction; the H1 2026 figure of $522 million and the H1 2025 figure of $463 million ARE filing-verified.

The balance sheet is improving, which is the best thing in this file. The 10-Q states: "Our consolidated debt-to-capital ratio was 40.8% and 42.1% as of June 30, 2026 and December 31, 2025, respectively" — a 130-basis-point improvement in six months — and: "Our senior debt is rated 'A−' by S&P Global Ratings, 'BBB+' by Fitch Ratings, Inc., 'Baa2' by Moody's."

2025-12-312026-06-30
Total assets$121,494M$126,438M
Additional paid-in capital$8,938M$8,917M
Retained earnings$35,393M$36,675M
Total shareholders' equity$43,882M$44,883M
Noncontrolling interests$144M$139M
Total equity$44,026M$45,022M
Shares outstanding220,723,898216,841,146

Capital return is substantial and steady: $1,358 million of buyback plus $749 million of dividends in the first half — $2,107 million, an annualised 5.1% of the market capitalisation — with the share count down 1.8% in six months and 14.3% since FY2020 (254.3 million diluted then; 217.9 million in the June quarter). The declared dividend is $1.72 per quarter, a $6.88 annual rate and a 1.82% yield.

3. Segments — a block that over-counts in two of three years

seg_prod reports two segments and the reconciliation quality varies wildly by year:

YearHealth BenefitsCarelon ServicesOtherEliminationsSuminc_a revenueRatio
FY2025$167,094M$71,716M—($41,689M)$197,121M$199,125M99.0%
FY2024$150,275M$53,922M—none$204,197M$176,810M115.5%
FY2023$148,571M$95,964M$479M($340M)$244,674M$171,340M142.8%

FY2025 reconciles to within 1.0% and is used with that caveat. FY2024 has NO eliminations line and over-counts by 15.5%. FY2023 over-counts by 42.8%, with a Carelon figure of $95,964 million that is implausible on any reading — larger than the FY2025 figure by 34% in a segment the company has been building. This is the CDNS / CSX over-count class in a year-specific form.

On the FY2025 figures, which are the only usable ones: Health Benefits $167,094 million and Carelon Services $71,716 million before $41,689 million of eliminations — so roughly 58% of Carelon's gross revenue is earned from Elevance's own Health Benefits segment. Carelon's FY2025 revenue grew 33.0% on the FY2024 figure, which if the block can be trusted at all is genuine scaling of the vertical-integration strategy. It also means the growth rate is computed across two years of which one over-counts by 15.5%, so the 33.0% is not reliable and is not used as a fact anywhere else in this dive.

seg_geo is COMPLETELY EMPTY — no entries at all. Elevance operates Blue Cross Blue Shield plans across fourteen US states and is effectively a domestic company, so the correct block is a single United States line; the payload provides nothing.

4. Valuation — priced in or room?

At $377.905 (market cap $81.956B, 216.84M shares):

TrailingFY2026EFY2027EFY2028E
Consensus adjusted EPS—$27.135 (14)$29.636 (14)$33.999 (4)
Company guidance—at least $26.75——
Growth—−9.5% (on FY2025's $29.988)+9.2%+14.7%
P/E15.0x (GAAP diluted TTM $25.20)13.9x12.8x11.1x
Revenue (consensus)$199,125M (FY2025)$196,962M (13)$201,375M (14)$212,419M (9)
Revenue growth+12.6%−1.1%+2.2%+5.5%
Benefit expense ratio (guided)88.3% (H1)90.2% ± 50 bps——
Dividend yield1.82%———
Total shareholder yield~5.1%———
Price / book1.83x———
Debt / capital (filing)40.8%———
Beta0.683———

Estimate coverage is good on the near years and thin beyond. 14 analysts on both FY2026 and FY2027 EPS — the FY2027 range of $29.081 to $31.270 is a 7.5% spread, among the narrowest in this batch — and only 4 on FY2028. FY2029 and FY2030 rest on TWO analysts each and are excluded from every conclusion.

Note that the FY2026 consensus REVENUE of $196,962 million is BELOW FY2025's actual $199,125 million — the street models a revenue decline, consistent with flat premiums and membership attrition.

est.ebitdaAvg and est.ebitAvg are REJECTED with the signature stated. In every year from FY2023 to FY2030, ebitdaAvg is exactly 6.1196% of revenueAvg and ebitAvg is exactly 5.2013%. Elevance's actual FY2025 EBITDA margin on the vendor's own income statement was 4.85%. The fabricated ratio is 26% too high and is applied mechanically across eight years. All forward valuation uses epsAvg, which tracks the company's adjusted basis: the FY2026 consensus of $27.135 sits 1.4% above management's "at least $26.75" guide, and the FY2025 figure of $29.988 is consistent with the reported adjusted result.

4a. What today's price assumes (the inversion)

At $377.905 — 13.9x FY2026 consensus and 12.8x FY2027 — the price embeds:

4b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+9.2%, FY2026E $27.135 to FY2027E $29.636) + multiple drift (roughly HELD, from 13.9x on today's forward year to about 13.5x on the then-forward year) + shareholder yield (+5.1%, being a 1.82% dividend and roughly 3.3% of buyback) ≈ +13%.

Our base assumes the multiple holds and applies a modest haircut to the FY2027 consensus, which is why $400 is only 5.8% above spot against the street's $444.06.

The structure of the return is favourable and worth naming: roughly two thirds earnings recovery and one third shareholder yield, with no re-rating required. The buyback alone — $1,358 million in six months, 3.3% of the market capitalisation annualised — is a meaningful component and is funded by an operating cash flow that doubled in the half. What makes this a Watch rather than a Buy is that the earnings-recovery leg has not started: management's own guidance says the second half of 2026 is worse than the first.

At 10x FY2027E the price is $296 (−21.7%). At 16x it is $474 (+25.5%).

4c. Variant perception (where we differ, what would surprise)

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $29.636, low $29.081, high $31.270; 14 analysts). Note the distribution is unusually narrow at 7.5%, so the multiple choice does more work here than the estimate does — the opposite of Phillips 66 in this batch — and the anchors below widen the multiple range deliberately to reflect that.

Base is 5.8% above spot; asymmetry roughly 1.77:1 (23.0% down, 40.8% up), before a shareholder yield of approximately 5.1%. That is genuinely close to the bar and it does not clear it, and the reason it does not is a single sentence in the company's own guidance: the second half is worse than the first.

5. Knowledge base — one name-level claim, and it says "late"

Raw entity hits: 1. Free-text hits: 4. Name-level claims on Elevance: 1. Discarded as name-level input: 4.

The case-sensitive entity sweep ran ELV, Elevance, Elevance Health and Anthem across all 52,021 distilled claims and returned one hit, with no homograph contamination — notable given that "Anthem" is also a common noun and a video-game title.

The one name-level claim, verbatim:

> 2025-07-12 · stance tagged bullish · conviction 80 · horizon: thesis · channel: business_breakdowns · no named speaker · entities: UnitedHealth Group, CVS Health, Cigna, Elevance, Humana · categories: managed care, vertical integration

> "UNH out-earns peers on integration depth; CVS is retail-heavy, Elevance late, Humana over-concentrated in Medicare Advantage — none match Optum's synergy."

Read on content rather than on the tag. The bullish stance attaches to UnitedHealth; the two words that concern this company are "Elevance late", which is a criticism of its vertical-integration position. This is a milder instance of the content-versus-tag problem confirmed on CME and ABNB and found again on ICE in this batch, and it is graded on content: mildly NEGATIVE for Elevance. It is also the most substantive independent judgment in this file, from a channel that specialises in business analysis, and it addresses precisely the strategic question — Carelon versus Optum — that determines whether this company deserves a higher multiple.

Four free-text hits, all sector-level, all at zero name-level weight — and one of them is the best argument for owning the security:

> 2025-07-12 · neutral · conviction 80 · channel: business_breakdowns · categories: health insurance, managed care

> "Health insurance is short-tail — one-year liabilities repriced every 12 months — so profit misses aren't perpetual; margins rebuild in rational competitive markets."

That sentence is the structural case for Elevance at 12.8x forward earnings in the middle of a margin shock, and it is stated more clearly than the company states it. An insurer that under-prices a book has twelve months to fix it. The consensus recovery from $27.14 to $29.64 to $34.00 across FY2026-FY2028 is that argument in numbers. Under the four-lane attribution policy it names no company and therefore carries no name-level conviction — which is stated rather than worked around, because it is the single most load-bearing idea in this dive.

The other three: brent_johnson, 2026-01-18, conviction 60, skill 0.7, BEARISH — "Shift to income-based (not borrowing-based) consumption hurts middlemen lenders; Trump supply-side reforms attack meat packers and health insurers" — a political-risk claim, low skill weight, and directionally consistent with the exchange and Medicaid pressure visible in the filings. invest_like_the_best, 2025-08-19, conviction 70 — "Deploying ~two dozen LLMs on the back end of a health insurer materially reduces operating costs and lets you hold prices lower" — relevant to an operating expense ratio that just rose 100 basis points, and unattached to any company. And lex_fridman, 2020-01-21, on government provision of health insurance, which is six years old and not about this industry's economics.

Attribution note: all five carry speaker: null and are channel-attributed — the weakest sourcing the four-lane policy admits. No management voice appears. No concentration test is meaningful across one name-level claim.

Conclusion. Breadth 1, claim count 1, net conviction negative-low. The Synthos knowledge base contains one claim naming Elevance Health and it calls the company late. Its most useful contribution is a sector principle that supports the recovery thesis and cannot be attributed to the security. Managed care is close to a genuine void in this store — five claims in total across the whole industry — and joins US gas midstream, cruise lines, acute-care hospitals, US refining, insurance brokerage, environmental services, diversified industrials, architectural coatings and regulated exchanges on that list.

6. Data integrity — three corrupted fields in one quarterly row

Six findings.

1. Three fields in the June 2026 inc_q row changed basis and are REJECTED — filing substituted.

Revenue ($50,474M), income before tax ($1,937M), net income ($1,463M) and diluted EPS ($6.71) all match the filing exactly. So four fields are right and three changed basis in the same row — the partial-row corruption pattern documented on Robinhood and ICE in this batch, here affecting three fields at once. Every June-quarter figure in this dive comes from the 10-Q.

2. seg_prod over-counts by 42.8% in FY2023 and 15.5% in FY2024 — REJECTED for those years. FY2023 sums to $244,674M against revenue of $171,340M, with a Carelon Services figure of $95,964M that is 34% larger than the FY2025 figure in a segment the company has been building. FY2024 sums to $204,197M against $176,810M with no eliminations line at all. FY2025 reconciles to within 1.0% ($197,121M against $199,125M) and is the only year used. The CDNS / CSX over-count class in a year-specific form. Consequence: the 33.0% Carelon growth rate implied by the FY2024-to-FY2025 comparison is computed across one broken year and is NOT used as a fact anywhere in this dive.

3. seg_geo is COMPLETELY EMPTY. No entries. Elevance operates Blue Cross Blue Shield plans across fourteen US states and is effectively wholly domestic, so the correct block is a single United States line equal to revenue; the payload provides nothing.

4. est.ebitdaAvg and est.ebitAvg carry a fixed-ratio fabrication signature — REJECTED. In every year from FY2023 to FY2030, ebitdaAvg is exactly 6.1196% of revenueAvg and ebitAvg is exactly 5.2013%. Elevance's actual FY2025 EBITDA margin was 4.85%. The fabricated ratio is 26% too high. All forward valuation uses epsAvg, which is sound: the FY2026 consensus of $27.135 sits 1.4% above management's "at least $26.75" adjusted guide.

5. The capital-expenditure check could not be completed for FY2025 and the H1 figures ARE filing-verified. The 10-Q reports "Purchases of property and equipment" of $522M (H1 2026) and $463M (H1 2025); the FY2025 annual line was not located in the extraction, so the vendor's annual capex field is unconfirmed. This dive does not quote a free-cash-flow yield for Elevance in any case, because for a health insurer operating cash flow includes movements in medical claims payable, unearned premium and policy liabilities — float rather than earnings. First-half operating cash flow doubled to $6,245M while shareholders' net income FELL 17.8%, which demonstrates the point: the two series do not measure the same thing.

6. Enterprise value is not meaningful for this business and is not used. The payload's leverage framework treats an insurer's balance sheet as if the liabilities were borrowings. The company publishes the relevant measure and this dive uses it: a consolidated debt-to-capital ratio of 40.8% at 2026-06-30 against 42.1% at 2025-12-31, with senior debt rated A− by S&P, BBB+ by Fitch and Baa2 by Moody's — all filing-verified.

Clean verifications worth recording. The share count is essentially EXACT: the 10-Q reports 216,841,146 shares outstanding at 2026-06-30 against 216.87 million implied by market capitalisation ÷ price — a 0.01% match, the tightest in this batch. est.epsAvg reconciles to company guidance within 1.4%. And the earn_cal block, while carrying only two entries, is consistent with the filings on both.

Non-equity tripwire — checked and passed. ELV is common stock, par value $0.01, NYSE-listed, per the 8-K cover pages. Price of $377.905 is not par-like; beta is 0.683; the dividend is a declared and rising quarterly rate ($1.72, a $6.88 annual rate, 1.82% yield); volume was 829K shares (~$313M of turnover); the 52-week band of $274.93 to $426.79 is a 55% range. Noncontrolling interests are $139 million. This is common equity.

Vendor composite rating — noted, and not used. B+ / 3 overall — the highest letter grade in this batch — with 5 on discounted cash flow, 4 on return on equity, 3 on return on assets and price-to-earnings and price-to-book, and 1 on debt-to-equity. The discounted-cash-flow score of 5 is built on an operating cash flow that is substantially insurance float, and the debt-to-equity score of 1 on a framework the company's own 40.8% debt-to-capital ratio contradicts.

7. Technicals

Today's move

ELV closed 2026-08-04 at $377.905, down 1.27% or $4.865 from $382.77, on 829,000 shares — the second-lightest volume in this batch. No company-specific filing is dated 2026-08-04; the last event was the 2026-07-15 earnings release and 10-Q, twenty days earlier.

The honest read: a valuation-supported entry into a guided deterioration. 12.8x FY2027 consensus, 11.5% below the high, 4.6% below the 50-day average, with a 5.1% shareholder yield and an improving debt-to-capital ratio — against a company that has told the market its medical loss ratio rises roughly 170 basis points in the second half. That is a better setup than Sherwin-Williams, Illinois Tool Works or Royal Caribbean in this batch and a worse one than the arithmetic alone suggests, and it is why the verdict is Watch with a written trigger rather than either Hold or Buy.

8. Insiders

The insider block for Elevance Health returned no usable transactions in this payload. There is nothing to report and nothing is invented to fill the section. A silent insider file is uninformative in both directions.

9. Verdict, kill-criteria and flip conditions

Watch.

The case against acting today is one sentence in the company's own guidance. Full-year 2026 benefit expense ratio guidance is 90.2% plus or minus 50 basis points. The first half ran 88.3%. That requires roughly 92% in the second half — a further 170-basis-point deterioration from the June quarter's 89.7%. On $82.3 billion of first-half premium revenue, 100 basis points is approximately $1.65 billion of annual pre-tax income, roughly $5.70 per share after tax. The third-quarter consensus of $4.70 against the June quarter's $7.45 adjusted actual shows the street has heard it. Underneath, adjusted EPS is falling for a second year — approximately $33.21, then $30, then a guide of at least $26.75 — the operating expense ratio rose 100 basis points to 11.1%, premium revenue grew 0.0%, and full-year GAAP guidance carries "approximately $6.90 per diluted share of net unfavorable items", a 25.8% adjustment described in a single clause.

The case for acting eventually is genuinely strong and it comes from the knowledge base rather than the company. "Health insurance is short-tail — one-year liabilities repriced every 12 months — so profit misses aren't perpetual; margins rebuild in rational competitive markets" (conviction 80). That is the correct structural description of this business and it is why the consensus has adjusted EPS recovering from $27.14 to $29.64 to $34.00 across FY2026-FY2028. Supporting it: a debt-to-capital ratio that IMPROVED from 42.1% to 40.8% in six months; senior debt rated A− by S&P; first-half operating cash flow that DOUBLED to $6,245 million; $1,358 million of buyback plus $749 million of dividends in the half, an annualised 5.1% of the market capitalisation; a share count down 14.3% since FY2020; and a valuation of 12.8x FY2027 consensus on 1.83x book.

Base fair value $400 (+5.8%), bear $291 (−23.0%), bull $532 (+40.8%) — 1.77:1. Genuinely close to the bar and not over it, and the thing standing between the two is a second half management has guided lower.

And the honest counterweight. 27 of 38 analysts rate this a buy, none rates it a sell, and the LOWEST target on the street is $391 — 3.5% above the price. Our $400 is 9.9% below their consensus and only 2.3% above their most bearish analyst. If the third-quarter benefit ratio comes in at or below 91%, this dive will look one quarter too cautious.

Pre-registered BUY trigger — either of these makes this Buy — Tactical:

Pre-registered KILL criteria — what would take this to Avoid:

Where ELV fits in the Synthos Framework Portfolio. No position today. Tracked on the healthcare-services watch list with two triggers: the third-quarter benefit-ratio condition above, and a $335 price. Initial size 2%, target 4%. Sizing note: this and HCA are the two names in this batch whose central variable is the same US health-coverage policy cycle, seen from opposite sides — HCA as the provider losing insured patients, Elevance as the insurer repricing the risk — and a portfolio should not take both triggers without recognising that it is doubling one exposure rather than diversifying. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $377.905, with the fair-value anchors, both triggers, the kill criteria and the 4a assumptions all gradeable. Also logged as a DATA flag: three fields in this payload's June-quarter inc_q row changed basis, its seg_prod block over-counts by 42.8% and 15.5% in FY2023 and FY2024, and its seg_geo block is empty.

Single biggest risk: the medical loss ratio, and the fact that management has already guided it higher. Elevance's benefit expense ratio was 88.9% in the June 2025 quarter, 89.7% in June 2026, 88.3% for the first half of 2026 — and the company's reaffirmed full-year guidance is 90.2% plus or minus 50 basis points, implying roughly 92% in the second half. On $82.3 billion of half-year premium revenue, one percentage point of that ratio is approximately $1.65 billion of annual pre-tax income against FY2025 pre-tax income of $6.71 billion — so a 200-basis-point miss is roughly half the company's profit. The drivers are medical cost trend, the acuity of the Medicaid population, and the composition of the individual exchange risk pool, none of which management sets and the last of which is the same legislative question that forced HCA to widen its own exchange assumption to $1.0-1.2 billion in this batch. The structural answer — that short-tail liabilities reprice within twelve months and margins rebuild — is correct, is stated at conviction 80 in the knowledge base, and is the reason this is a Watch with a written trigger rather than an Avoid. It has not happened yet, and management's own guidance says it does not happen this year.

Provenance & disclosures